Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
Women’s History Month: Breast cancer in the White House
FreeIn the Archives

Women’s History Month: Breast cancer in the White House

March 03, 2023
Vol.49 No.09
By Stacy Wentworth
Clinical Roundup

Updated NCCN guidelines will reduce potentially unnecessary breast cancer treatments

February 17, 2023
Vol.49 No.07
In Brief

Four UPMC/Pitt scientists receive funding from Breast Cancer Research Foundation

February 10, 2023
Vol.49 No.06
Funding Opportunities

DoD Breast Cancer Research Program funding opportunities for FY23

February 10, 2023
Vol.49 No.06
Clinical Roundup

Oncolytic virus treatment produces promising results for TNBC in phase II study

February 10, 2023
Vol.49 No.06
Clinical Roundup

Uncertainty about breast cancer risk and screening choices increase with breast density awareness

February 10, 2023
Vol.49 No.06
Clinical Roundup

Study finds large gap in breast cancer treatment recommendations for patients aged 70 vs 69

February 03, 2023
Vol.49 No.05
Clinical Roundup

SWOG S1416 study results show PARP inhibitor benefit in “BRCA-like” breast cancer

February 03, 2023
Vol.49 No.05
Drugs & Targets

Orserdu & companion diagnostic for ER+, HER2-, ESR1-mutated advanced breast cancer receive FDA approval

February 03, 2023
Vol.49 No.05
Clinical Roundup

Medical College of Wisconsin scientists find marker that may predict immunotherapy response in ER+ breast cancer

January 27, 2023
Vol.49 No.04

Posts navigation

Previous1…222324…32Next

Trending Stories

  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH
  • Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
  • FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
    Draft guidance consolidates trial design updates for developers
  • Trump imposes up to 100% tariff on some brand name pharmaceutical companies
  • “This is not about protecting life”: Supreme Court overturn of Roe v. Wade threatens lives of cancer patients, doctors

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account